BRUGIA, MARCO

BRUGIA, MARCO  

Medicina Sperimentale e Clinica  

Mostra records
Risultati 1 - 20 di 32 (tempo di esecuzione: 0.052 secondi).
Titolo Data di pubblicazione Autore(i) File
A case report of eyelid Merkel cell carcinoma occurring under treatment with nivolumab for a lung adenocarcinoma. 2018 Lavacchi D, Nobili S, Brugia M, Paderi A, Fancelli S, Caliman E, Vergoni F, Mini E.
A transcriptomic profile predicts clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 2016 Mini, E; D’Aurizio, R; Perrone, G; Magi, A; Lapucci, A; Tassi, R; Napoli, C; Picariello, L; Landini, I; Brugia, M; Mazzei, T; Tonelli, F; Nobili, S
Aflibercept plus folfiri as second-line treatment for metastatic colorectal cancer: A single-institution real-life experience 2021 Lavacchi D.; Roviello G.; Giommoni E.; Dreoni L.; Derio S.; Brugia M.; Amedei A.; Pillozzi S.; Antonuzzo L.
Analysis of Prognostic Factors for Resected Synchronous and Metachronous Liver Metastases from Colorectal Cancer. 2018 Bartolini I, Ringressi MN, Melli F, Risaliti M, Brugia M, Mini E, Batignani G, Bechi P, Boni L, Taddei A.
Association of systemic steroid treatment and outcome in patients treated with immune checkpoint inhibitors: A real-world analysis 2021 Paderi A.; Gambale E.; Botteri C.; Giorgione R.; Lavacchi D.; Brugia M.; Mazzoni F.; Giommoni E.; Bormioli S.; Amedei A.; Pillozzi S.; Cerinic M.M.; Antonuzzo L.
Chasing the target: New phenomena of resistance to novel selective ret inhibitors in lung cancer. updated evidence and future perspectives 2021 Fancelli S.; Caliman E.; Mazzoni F.; Brugia M.; Castiglione F.; Voltolini L.; Pillozzi S.; Antonuzzo L.
Circulating tumour cells and cell-free DNA as a prognostic factor in metastatic colorectal cancer: the OMITERC prospective study 2021 Salvianti, Francesca; Gelmini, Stefania; Mancini, Irene; Pazzagli, Mario; Pillozzi, Serena; Giommoni, Elisa; Brugia, Marco; Di Costanzo, Francesco; Galardi, Francesca; De Luca, Francesca; Castiglione, Francesca; Messerini, Luca; Pinzani, Pamela; Antonuzzo, Lorenzo
Current status and future perspectives in HER2 positive advanced gastric cancer 2022 Roviello, G; Catalano, M; Iannone, L F; Marano, L; Brugia, M; Rossi, G; Aprile, G; Antonuzzo, L
D13Global gene expression profile reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 2016 Tassi, R.; Mini, E.; D'Aurizio, R.; Perrone, G.; Magi, A.; Lapucci, A.; Napoli, C.; Picariello, L.; Brugia, M.; Landini, I.; Mazzei, T.; Tonelli, F.; Nobili, S.
Emerging drugs in refractory colorectal cancer 2015 Nobili, S; Galletta, A; Brugia, M; Tassi, R; Petreni, P; Landini, I; Mini, E
Endocrine-related adverse events in a large series of cancer patients treated with anti-PD1 therapy 2021 Rubino R, Marini A, Roviello G, Presotto EM, Desideri I, Ciardetti I, Brugia M, Pimpinelli N, Antonuzzo L, Mini E, Livi L, Maggi M, Peri A.
Evaluation of Fruquintinib in the Continuum of Care of Patients with Colorectal Cancer 2023 Lavacchi, Daniele; Roviello, Giandomenico; Guidolin, Alessia; Romano, Silvia; Venturini, Jacopo; Caliman, Enrico; Vannini, Agnese; Giommoni, Elisa; Pellegrini, Elisa; Brugia, Marco; Pillozzi, Serena; Antonuzzo, Lorenzo
Fluoropyrimidine-related toxicity in gastrointestinal cancer patients. Assessment of risk factors. 2015 Tassi, R; Perrone, G; Brugia, M; Simi, L; Petreni, P; Mori, E; Landini, I; Pazzagli, M; Mazzei, T; Mini, E; Nobili, S
Global gene expression profile reveals a distinct transcriptomic profile predictive of clinical outcome in stage III colorectal cancer patients treated with adjuvant chemotherapy 2016 Tassi, R; Mini, E; D'Aurizio, R; Perrone, G; Magi, A; Lapucci, A; Napoli, C; Picariello, L; Brugia, M; Landini, I; Mazzei, T; Tonelli, F; Nobili, S
In Regard to "Activity of EGFR TKIs in Caucasian Patients With NSCLC Harbouring Potentially Sensitive Uncommon EGFR Mutations" 2020 Caliman, Enrico; Petreni, Paolo; Brugia, Marco; Antonuzzo, Lorenzo; Mazzoni, Francesca
Long-term response of more than 9 years to regorafenib in a heavily pretreated patient with metastatic colorectal cancer 2023 Cosso, Federica; Lavacchi, Daniele; Fancelli, Sara; Caliman, Enrico; Brugia, Marco; Rossi, Gemma; Winchler, Costanza; Pillozzi, Serena; Antonuzzo, Lorenzo
Mutations matter: An observational study of the prognostic and predictive value of KRAS mutations in metastatic colorectal cancer 2022 Lavacchi, Daniele; Fancelli, Sara; Roviello, Giandomenico; Castiglione, Francesca; Caliman, Enrico; Rossi, Gemma; Venturini, Jacopo; Pellegrini, Elisa; Brugia, Marco; Vannini, Agnese; Bartoli, Caterina; Cianchi, Fabio; Pillozzi, Serena; Antonuzzo, Lorenzo
Osteonecrosis of the Jaw and Angiogenesis inhibitors: A Revival of a Rare but Serous Side Effect 2017 Antonuzzo, Lorenzo; Lunghi, Alice; Petreni, Paolo; Brugia, Marco; Laffi, Alice; Giommoni, Elisa; Mela, Marinella M; Mazzoni, Francesca; Balestri, Vanni; Costanzo, Francesco Di
Pathological complete response achieved with FLOT chemotherapy in two patients with MSI-H esophagogastric junction and gastric adenocarcinoma 2024 Cosso, Federica; Lavacchi, Daniele; Messerini, Luca; Briganti, Vittorio; Castiglione, Francesca; Brugia, Marco; Berti, Valentina; Fancelli, Sara; Cianchi, Fabio; Vannini, Agnese; Pillozzi, Serena; Antonuzzo, Lorenzo
Perioperative Tailored Treatments for Gastric Cancer: Times Are Changing 2023 Lavacchi, Daniele; Fancelli, Sara; Buttitta, Eleonora; Vannini, Gianmarco; Guidolin, Alessia; Winchler, Costanza; Caliman, Enrico; Vannini, Agnese; Giommoni, Elisa; Brugia, Marco; Cianchi, Fabio; Pillozzi, Serena; Roviello, Giandomenico; Antonuzzo, Lorenzo